Pacific region influenza surveillance for oseltamivir resistance.

Authors:
Address: State Laboratories Division, Hawaii Department of Health, Pearl City, HI 96782, USA.
Journal:

Publication:

abstract

BACKGROUND:

Hawaii and the United States-affiliated Pacific islands (USAPI) host over 8 million travelers annually, most of whom originate in Asia, Australia, and the Americas where prevalence of oseltamivir resistance in 2009 pandemic influenza A (H1N1) has been reported to be 2.5-3.5%.

OBJECTIVE:

To survey a collection of samples from Hawaii and the USAPI that had tested positive for the 2009 pandemic influenza A (H1N1) virus by RTI-PCR to assess whether antiviral resistance emerged in these island communities during the 2009 H1N1 pandemic.

STUDY DESIGN:

We examined RNA extracted from Hawaiian and USAPI cases for the neuraminidase H275Y mutation associated with oseltamivir resistance by pyrosequencing.

RESULTS:

Two hundred and sixty-three (263) 2009 pandemic influenza A (H1N1) positive specimens were tested and 263/263 (100%) were shown to lack the mutation most commonly associated with oseltamivir resistance.

CONCLUSIONS:

There was no evidence of oseltamivir resistant A(H1N1)pdm09 virus during the 2009 pandemic in the Pacific islands despite considerable travel exposure. Geographic isolation, the lack of a "second wave" of pandemic influenza, judicious antiviral use, aggressive vaccination, and below average tourism due to the global economic crisis may have been contributing factors. Continued surveillance and vigilance is necessary to monitor unpredictable influenza activity.

Related Articles
Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1) 2009 pandemic in the Asia-Pacific region, March 2009 to March 2010.
Euro Surveill. 2011
Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1) 2009 pandemic in the Asia-Pacific region, March 2009 to March 2010.
Hurt AC, Deng YM, Ernest J, Caldwell N, Leang L, Iannello P, Komadina N, Shaw R, Smith D, Dwyer DE, et al. Euro Surveill. 2011 Jan 20; 16(3). Epub 2011 Jan 20.
Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness.
J Antimicrob Chemother. 2011
Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness.
Brookes DW, Miah S, Lackenby A, Hartgroves L, Barclay WS. J Antimicrob Chemother. 2011 Mar; 66(3):466-70. Epub 2010 Dec 16.
Evaluation of a rapid molecular algorithm for detection of pandemic influenza A (H1N1) 2009 virus and screening for a key oseltamivir resistance (H275Y) substitution in neuraminidase.
J Clin Virol. 2010
Evaluation of a rapid molecular algorithm for detection of pandemic influenza A (H1N1) 2009 virus and screening for a key oseltamivir resistance (H275Y) substitution in neuraminidase.
van der Vries E, Jonges M, Herfst S, Maaskant J, Van der Linden A, Guldemeester J, Aron GI, Bestebroer TM, Koopmans M, Meijer A, et al. J Clin Virol. 2010 Jan; 47(1):34-7. Epub 2009 Oct 25.
Review Systematic review of influenza resistance to the neuraminidase inhibitors.
BMC Infect Dis. 2011
Review Systematic review of influenza resistance to the neuraminidase inhibitors.
Thorlund K, Awad T, Boivin G, Thabane L. BMC Infect Dis. 2011 May 19; 11:134. Epub 2011 May 19.
Review The use of antiviral agents for the management of severe influenza.
Crit Care Med. 2010
Review The use of antiviral agents for the management of severe influenza.
Smith JR, Ariano RE, Toovey S. Crit Care Med. 2010 Apr; 38(4 Suppl):e43-51.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.